Otto Bock Healthcare LP

Otto Bock Healthcare LP, a for-profit medical device manufacturer headquartered in Austin, Texas, operates as a prime contractor supplying prosthetic and orthotic devices, artificial limbs, and rehabilitation services directly to the Department of Veterans Affairs, Defense Health Agency, and Department of Defense components. The company competes on full-and-open basis with no SBA set-aside designations and does not pursue federal contracts under minority, SDVOSB, WOSB, 8(a), or HUBZone categories.

Otto Bock's federal footprint centers on prosthetic and orthotic device procurement. The company holds a $265 million single-award Indefinite Delivery Contract with the VA National Acquisition Center (awarded February 2025, extending through February 2030) that consolidates VA procurement of prosthetic feet, knee units, liners, modular adapters, and suspension systems across VA prosthetic clinics nationwide via the Distribution Logistics Center's Remote Order Entry System. The company also maintains a $5 million single-award Blanket Purchase Agreement with the Defense Health Agency (awarded November 2023, extending through November 2028) for prosthetic and orthotic devices, surgical instruments, medical equipment, and rehabilitation services, and a $350 thousand single-award BPA with DHA for Genium X3 mechanical knees and rehabilitation braces (awarded January 2026, extending through January 2029). Recent representative work includes a $30.4 million delivery order from Veterans Integrated Service Network 10 for Empower microprocessor foot prosthetics (June 2026), a $52.1 million purchase order from VISN 6 for C-Brace orthotic systems (November 2025), a $50.8 million purchase order from VISN 22 for prosthetics and artificial limbs (September 2025), and a $190.9 million purchase order from Defense Health Agency for arm prosthetics (March 2025).

Customer concentration sits heavily with the VA's regional service networks and DHA. The top five customers by award count account for 26 percent of awards and are led by VISN 8 (317 awards, $7.2 million combined potential value), Navy Bureau of Medicine and Surgery (239 awards, $21.9 million), VISN 17 (201 awards, $5.5 million), VISN 2 (195 awards, $5.5 million), and VISN 22 (195 awards, $4.5 million). By dollar concentration, the top five account for 30 percent of combined potential value: VISN 19 ($32.3 million across 170 awards), Defense Health Agency ($30.5 million across 89 awards), VISN 12 ($29.2 million across 88 awards), Army Medical Command ($25.1 million across 173 awards), and Navy Bureau of Medicine and Surgery ($21.9 million). The divergence between count and dollar rankings reflects a customer mix where VISN 19 and DHA anchor most dollars despite lower award frequency, while VISN 8 generates high volume in smaller individual orders.

Otto Bock's activity has remained stable in the 50–62 award range annually over the past five years (2022–2026), with 4,452 total awards carrying combined potential value of $463.8 million and $108.9 million in obligated dollars across 29 distinct customer agencies. The company operates across primary NAICS categories of Surgical Appliance and Supplies Manufacturing (1,995 awards) and Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (1,371 awards), with PSC concentration in Medical and Surgical Instruments, Equipment, and Supplies (2,997 awards) and Maintenance/Repair/Rebuild of Medical Equipment (824 awards). Otto Bock serves as sole prime on all identified awards with no subcontractor relationships in the source data; the company operates as a direct supplier rather than a systems integrator. A single grant sub-award appears: University of Utah prime recipient on a research grant for high-performance powered ankle/foot prosthetics for below-knee amputees (Otto Bock as sub-recipient, award date February 2025). The recompete cliff in the next 24 months is minimal—ten awards (combined potential value $262 thousand) reaching ultimate completion, suggesting stable near-term contract continuity within the VA and DHA networks.